8-K filing — CUMBERLAND PHARMACEUTICALS INC (CPIX)
Filed: 2026-08-28 AccNo: 0001087294-26-000064 Size: 141 KB Item 7.01: Regulation FD Disclosure
Stocks · News reference
Redhill Biopharma Announces FDA Rare Pediatric Disease Designation For Opaganib For The Treatment Of Neuroblastoma
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Cumberland Q2 Adj. EPS $(0.20) Down From $(0.13) YoY, Sales $166.458K Down From $380.797K YoY
Cumberland (NASDAQ:CPIX) reported quarterly losses of $(0.20) per share. This is a 53.85 percent decrease over losses of $(0.13) per share from the same period last year. The company reported $166.458 thousand in sales
Cumberland Pharmaceuticals Declares $1.50/Share Special Dividend
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), an innovation-focused biopharmaceutical company developing new products for rare diseases, announced today that its Board of Directors has authorized and declared a special
Cumberland Pharma Advances Duchenne Program With New Safety, Efficacy Data
Cumberland Pharma shares rose after Phase 2 data showed ifetroban improved heart function in Duchenne muscular dystrophy patients.
RedHill Biopharma Announces Deal To Acquire Global Rebyota And U.S. Clenpiq Commercialization Rights From Ferring For $12M Upfront, Plus Milestones And Tiered Royalties
Nontuberculous Mycobacterial Infections Market to Showcase Growth at a CAGR of 12.6% During the Forecast Period (2026–2036), Driven by Rising Disease Burden and Emerging Therapies | DelveInsight
The nontuberculous mycobacterial (NTM) infections market is projected to grow at a CAGR of 12.6% from 2026-2036, valued at USD 750 million in 2025. Growth is driven by rising disease prevalence, improved diagnostics, and emerging therapies including Omadacycline (NUZYRA), MRX-5, Epetraborole, and RHB-204. The US represents the largest market with approximately 400,000 diagnosed NTM cases across the 7MM countries.